Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · IEX Real-Time Price · USD
1.660
-0.075 (-4.32%)
At close: Jul 19, 2024, 4:00 PM
1.700
+0.040 (2.41%)
Pre-market: Jul 22, 2024, 7:33 AM EDT

PACB Revenue

Pacific Biosciences of California had revenue of $200.43M in the twelve months ending March 31, 2024, with 49.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $38.81M. In the year 2023, Pacific Biosciences of California had annual revenue of $200.52M with 56.29% growth.

Revenue (ttm)
$200.43M
Revenue Growth
+49.54%
P/S Ratio
2.26
Revenue / Employee
$251,798
Employees
796
Market Cap
452.11M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023200.52M72.22M56.29%
Dec 31, 2022128.30M-2.21M-1.69%
Dec 31, 2021130.51M51.62M65.43%
Dec 31, 202078.89M-12.00M-13.20%
Dec 31, 201990.89M12.27M15.60%
Dec 31, 201878.63M-14.84M-15.88%
Dec 31, 201793.47M2.75M3.04%
Dec 31, 201690.71M-2.07M-2.23%
Dec 31, 201592.78M32.19M53.12%
Dec 31, 201460.59M32.41M115.02%
Dec 31, 201328.18M2.20M8.46%
Dec 31, 201225.98M-7.88M-23.27%
Dec 31, 201133.86M32.19M1,922.88%
Dec 31, 20101.67M1.54M1,140.00%
Dec 31, 2009135.00K-766.00K-85.02%
Dec 31, 2008901.00K-1.26M-58.34%
Dec 31, 20072.16M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Bioventus 522.74M
Voyager Therapeutics 119.04M
EyePoint Pharmaceuticals 50.02M
MaxCyte 44.05M
Nano-X Imaging 10.01M
Absci 5.35M
Altimmune 410.00K
Revenue Rankings